Florida Cancer Specialists

Lake Mary, Florida 32746

2 studies enrolling now · 18 studies all time

What they study most

ALK Genomic Tumor Aberrations, Acral Lentiginous Melanoma, Acute Myeloid Leukemia, Adamantinomatous Craniopharyngioma, Adenoid Cystic Carcinoma, Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Tumors, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, Anogenital Cancer, Brain Tumor, Primary

Studies at this site

• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting now
• FOG-001 in Locally Advanced or Metastatic Solid Tumors — Recruiting now
• Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma — Recruiting now
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy — Recruiting now
• A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer — Recruiting now
• Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications — Stopped early
• Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers — Stopped early
• A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors — Running, not enrolling
• A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors — Completed
• Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors — Stopped early
• Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma — Completed
• Phase I Study of CPI-300 in Patients With Advanced Tumors — Completed
• PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL — Completed
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies — Stopped early
• A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas — Completed
• A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies — Completed
• A Study of PRT1419 in Patients With Advanced Solid Tumors — Completed
• A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies — Completed